跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TABRECTA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
TABRECTA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Approved
STANDARD
TABRECTA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Novartis Europharm Limited
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jul 12, 2022
Approval ID
406e14f4a054b43a
Company
Novartis Europharm Limited
Type
Standard
Approval Details
Approval Id
406e14f4a054b43a
Drug Cima Aemps Name
TABRECTA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number
1221650002
Holder Company Name
Novartis Europharm Limited
Marketing Company Name
Novartis Farmaceutica S.A.
Holder Company Detail Path
/organization/novartis-europharm-limited
Authorization Date
2022-07-12
Dosage Form
COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose
150 mg
Route Of Administration
VÍA ORAL
Prescription Type
Diagnóstico Hospitalario
Commercialized
Yes
Company Name
Novartis Europharm Limited
Company Detail Path
/organization/novartis-europharm-limited
Company Information
Pharmaceutical Company Name
NOVARTIS EUROPHARM LIMITED
Country Name
United Kingdom
City Name
camberley,country_gb
Address
200 Frimley Business Park
Active Ingredients
CAPMATINIB DIHIDROCLORURO MONOHIDRATO
183 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jul 12, 2022
Approval ID
406e14f4a054b43a
Type
Standard
Back to CIMA-AEMPS Approvals
